Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

References

• SmithARomanEHowellDThe Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service researchBr J Haematol2010148573975319958356
   PubMed Web of Science ®Google Scholar
• MartelliMFerreriAJAgostinelliCdi RoccoAPfreundschuhMPileriSADiffuse large B-cell lymphomaCrit Rev Oncol Hematol201387214617123375551
   PubMed Web of Science ®Google Scholar
• SmithAHowellDCrouchSCohort profile: the Haematological Malignancy Research Network (HMRN): a UK population-based patient cohortInt J Epidemiol2018473700700g
   PubMed Web of Science ®Google Scholar
• Le GouillSTalmantPTouzeauCThe clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangementHaematologica200792101335134218024371
   PubMed Web of Science ®Google Scholar
• HarrisNLJaffeESDieboldJFlandrinGMuller-HermelinkHKVardimanJLymphoma classification – from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasmsAnn Oncol200011Suppl 1S3S10
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood2016127202375239026980727
   PubMed Web of Science ®Google Scholar
• LinPMedeirosLJHigh-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosisHaematologica200792101297130118024366
   PubMed Web of Science ®Google Scholar
• HuSXu-MonetteZYTzankovAMYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium programBlood2013121204021403123449635
   PubMed Web of Science ®Google Scholar
• JohnsonNASlackGWSavageKJConcurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneJ Clin Oncol201230283452345922851565
   PubMed Web of Science ®Google Scholar
• DunleavyKRoschewskiMAbramsonJSPreliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphomaBlood2014124395
   Web of Science ®Google Scholar
• YoonSOJeonYKPaikJHMYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) typeHistopathology200853220521718752503
   PubMed Web of Science ®Google Scholar
• KusumotoSKobayashiYSekiguchiNDiffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a “non-germinal center phenotype”Am J Surg Pathol20052981067107316006802
   PubMed Web of Science ®Google Scholar
• MonniOJoensuuHFranssilaKKlefstromJAlitaloKKnuutilaSBcl2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphomaBlood1997903116811749242549
   PubMed Web of Science ®Google Scholar
• SarkozyCTraverse-GlehenACoiffierBDouble-hit and double-protein-expression lymphomas: aggressive and refractory lymphomasLancet Oncol20151615e555e56726545844
   PubMedGoogle Scholar
• KuritaDMiuraKNakagawaMDose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphomaInt J Hematol2015101658559325776837
   PubMed Web of Science ®Google Scholar
• ChenAILeonardJTOkadaCYOutcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphomaLeuk Lymphoma20185981884188929199519
   PubMed Web of Science ®Google Scholar
• PetrichAMGandhiMJovanovicBImpact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysisBlood2014124152354236125161267
   PubMed Web of Science ®Google Scholar
• GreerJPDsMLiSRole of aggressive chemotherapeutic regimens in double hit lymphoma- can alternate aggressive induction regimens overcome the poor prognosis of diffuse large B cell lymphoma?Blood201312243614361
   Google Scholar
• MunozJVekariaMHanbaliAJanakiramanNProgression of double-hit lymphoma in the midst of R-hyper CVADAm J Hematol2013881878822488177
   PubMed Web of Science ®Google Scholar
• SunHSavageKJKarsanAOutcome of patients with double-hit lymphomas treated with CODOX-M/IVAC + R followed by hematopoietic stem cell transplantation in British ColumbiaBlood20131221788
   Google Scholar
• WilsonWHDunleavyKPittalugaSPhase II study of dose-adjusted epoch and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersJ Clin Oncol200826162717272418378569
   PubMed Web of Science ®Google Scholar
• FisherRIGaynorERDahlbergSComparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphomaN Engl J Med199332814100210067680764
   PubMed Web of Science ®Google Scholar
• MangasarovaYKMagomedovaAUNesterovaESTherapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: the first resultsTer Arkh20168873742
   PubMed Web of Science ®Google Scholar
• StiffPJUngerJMCookJRAutologous transplantation as consolidation for aggressive non-Hodgkin’s lymphomaN Engl J Med2013369181681169024171516
   PubMed Web of Science ®Google Scholar
• ChiappellaAMartelliMAngelucciERituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell Lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyLancet Oncol20171881076108828668386
   PubMed Web of Science ®Google Scholar
• PejšaVPrkaŽLucijanićMRituximab with dose-adjusted epoch as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patientsCroat Med J2017581404828252874
   PubMed Web of Science ®Google Scholar
• HansCPWeisenburgerDDGreinerTCConfirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood2004103127528214504078
   PubMed Web of Science ®Google Scholar
• MillerABHoogstratenBStaquetMWinklerAReporting results of cancer treatmentCancer19814712072147459811
   PubMed Web of Science ®Google Scholar
• ChesonBDHorningSJCoiffierBReport of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working groupJ Clin Oncol19991741244124410561185
   PubMed Web of Science ®Google Scholar
• ChesonBDPfistnerBJuweidMERevised response criteria for malignant lymphomaJ Clin Oncol200725557958617242396
   PubMed Web of Science ®Google Scholar
• HerreraAFMeiMLowLRelapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantationJ Clin Oncol2017351243128034071
   PubMed Web of Science ®Google Scholar
• OkiYNooraniMLinPDouble hit lymphoma: the MD Anderson Cancer Center clinical experienceBr J Haematol2014166689190124943107
   PubMed Web of Science ®Google Scholar
• CohenJBGeyerSMLozanskiGComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalCancer2014120111677168524578014
   PubMed Web of Science ®Google Scholar
• TomitaNTokunakaMNakamuraNClinicopathological features of lymphoma/leukemia patients carrying both Bcl2 and Myc translocationsHaematologica200994793594319535347
   PubMed Web of Science ®Google Scholar
• SavageKJSlackGWMottokAImpact of dual expression of myc and Bcl2 by immunohistochemistry on the risk of CNS relapse in DLBCLBlood2016127182182218826834242
   PubMed Web of Science ®Google Scholar
• HowlettCSnedecorSJLandsburgDJFront-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisBr J Haematol2015170450451425907897
   PubMed Web of Science ®Google Scholar
• RécherCCoiffierBHaiounCIntensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell Lymphoma (LNH03-2B): an open-label randomised phase 3 trialThe Lancet2011378980618581867
   PubMed Web of Science ®Google Scholar
• SunHSavageKJKarsanAOutcome of patients with non-Hodgkin lymphomas with concurrent myc and Bcl2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantationClin Lymphoma Myeloma Leuk201515634134825656914
   PubMed Web of Science ®Google Scholar